At a glance
ClinicalIndex Comparison RecordN/ACompleted· 63 enrolled
Drug / intervention
Not specified
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
VPRIV Drug Use-Result Survey (Japan)
In Brief
An observational study for Gaucher Disease. Completed, enrolled 63 participants across 35 sites.
Detailed Summary
The objective of this post-marketing survey study is to collect data to determine the safety and efficacy of velaglucerase alfa (VPRIV) in participants with Gaucher disease who are new to therapy or have been switched from another therapeutic agent for Gaucher disease.
Study Details
Study Typeobservational
Allocation--
Masking--
Primary Purpose--
ConditionsGaucher Disease
CountriesJapan
Collaborators--
Timeline
N/ACompletedFinished
201520162017201820192020202120222023202420252026
Enrollment StartSep 2014
First PostedAug 2018
Primary CompletionMay 2024
TodayJul 2026
First PostedAug 10, 2018
Enrollment StartSep 2, 2014
Primary CompletionMay 14, 2024
TodayJul 2, 2026
Enrollment to primary: 9.7 yearsPosted 7.9 years ago